These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

631 related articles for article (PubMed ID: 24051998)

  • 61. Lack of nonspecific protection against all-cause nonrotavirus gastroenteritis by vaccination with orally administered rotavirus vaccine.
    Grant L; Watt J; Moulton L; Weatherholtz R; Reid R; Santosham M; O'Brien K
    J Pediatr Gastroenterol Nutr; 2013 Jun; 56(6):635-40. PubMed ID: 23343932
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States.
    Wang FT; Mast TC; Glass RJ; Loughlin J; Seeger JD
    Pediatr Infect Dis J; 2013 Mar; 32(3):278-83. PubMed ID: 23014356
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Rotavirus genotypes and clinical outcome of natural infection based on vaccination status in the post-vaccine era.
    Kozawa K; Higashimoto Y; Kawamura Y; Miura H; Negishi T; Hattori F; Ihira M; Komoto S; Taniguchi K; Yoshikawa T
    Hum Vaccin Immunother; 2022 Dec; 18(1):2037983. PubMed ID: 35240934
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Disease Burden of Rotavirus Gastroenteritis in Children Residing in Germany: A Retrospective, Hospital-based Surveillance.
    Kowalzik F; Zepp F; Hoffmann I; Binder H; Lautz D; van Ewijk R; Knuf M; Tenenbaum T; Laass M; Reuter T; Schulze-Rath R; Marron M
    Pediatr Infect Dis J; 2016 Jan; 35(1):97-103. PubMed ID: 26421806
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Case-control study of the effectiveness of vaccination with pentavalent rotavirus vaccine in Nicaragua.
    Mast TC; Khawaja S; Espinoza F; Paniagua M; Del Carmen LP; Cardellino A; Sánchez E
    Pediatr Infect Dis J; 2011 Nov; 30(11):e209-15. PubMed ID: 21768920
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of rotavirus vaccination in Australian children below 5 years of age: a database study.
    Pendleton A; Galic M; Clarke C; Ng SP; Ledesma E; Ramakrishnan G; Liu Y
    Hum Vaccin Immunother; 2013 Aug; 9(8):1617-25. PubMed ID: 23733041
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Mucosal Immunity and acute viral gastroenteritis.
    Rose MA
    Hum Vaccin Immunother; 2014; 10(7):2112-4. PubMed ID: 25424826
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Effectiveness of pentavalent rotavirus vaccine in a large urban population in the United States.
    Boom JA; Tate JE; Sahni LC; Rench MA; Hull JJ; Gentsch JR; Patel MM; Baker CJ; Parashar UD
    Pediatrics; 2010 Feb; 125(2):e199-207. PubMed ID: 20083525
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
    Ciarlet M; Schödel F
    Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Effectiveness of monovalent and pentavalent rotavirus vaccines in Japanese children.
    Araki K; Hara M; Tsugawa T; Shimanoe C; Nishida Y; Matsuo M; Tanaka K
    Vaccine; 2018 Aug; 36(34):5187-5193. PubMed ID: 30037664
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Long-term Consistency in Rotavirus Vaccine Protection: RV5 and RV1 Vaccine Effectiveness in US Children, 2012-2013.
    Payne DC; Selvarangan R; Azimi PH; Boom JA; Englund JA; Staat MA; Halasa NB; Weinberg GA; Szilagyi PG; Chappell J; McNeal M; Klein EJ; Sahni LC; Johnston SH; Harrison CJ; Baker CJ; Bernstein DI; Moffatt ME; Tate JE; Mijatovic-Rustempasic S; Esona MD; Wikswo ME; Curns AT; Sulemana I; Bowen MD; Gentsch JR; Parashar UD
    Clin Infect Dis; 2015 Dec; 61(12):1792-9. PubMed ID: 26449565
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Effectiveness of monovalent rotavirus vaccine in a high-income, predominant-use setting.
    Doll MK; Buckeridge DL; Morrison KT; Gagneur A; Tapiero B; Charest H; Quach C
    Vaccine; 2015 Dec; 33(51):7307-7314. PubMed ID: 26546262
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Australian Rotavirus Surveillance Program annual report, 2013.
    Kirkwood CD; Roczo-Farkas S;
    Commun Dis Intell Q Rep; 2014 Dec; 38(4):E334-42. PubMed ID: 25631596
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Is rotavirus still a major cause for diarrheal illness in hospitalized pediatric patients after rotavirus vaccine introduction in the Saudi national immunization program?
    Hegazi MA; Sayed MH; Sindi HH; Bekhit OE; El-Deek BS; Alshoudri FMY; Noorelahi AK
    Medicine (Baltimore); 2017 Apr; 96(15):e6574. PubMed ID: 28403085
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
    Abbott C; Tiede B; Armah G; Mahmoud A
    Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Cost-effectiveness of universal rotavirus vaccination in reducing rotavirus gastroenteritis in Ireland.
    Tilson L; Jit M; Schmitz S; Walsh C; Garvey P; McKeown P; Barry M
    Vaccine; 2011 Oct; 29(43):7463-73. PubMed ID: 21821085
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Sustained protection from pentavalent rotavirus vaccination during the second year of life at a large, urban United States pediatric hospital.
    Boom JA; Tate JE; Sahni LC; Rench MA; Quaye O; Mijatovic-Rustempasic S; Patel MM; Baker CJ; Parashar UD
    Pediatr Infect Dis J; 2010 Dec; 29(12):1133-5. PubMed ID: 20634776
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Impact and effectiveness of pentavalent rotavirus vaccine in children <5 years of age in Burkina Faso.
    Bonkoungou IJO; Aliabadi N; Leshem E; Kam M; Nezien D; Drabo MK; Nikiema M; Ouedraogo B; Medah I; Konaté S; Ouédraogo-Traoré R; Sangaré L; Kam L; Yé D; Ouattara M; Biey JN; Mwenda JM; Tate JE; Parashar UD
    Vaccine; 2018 Nov; 36(47):7170-7178. PubMed ID: 29290478
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Safety of the pentavalent rotavirus vaccine (PRV), RotaTeq(®), in Kenya, including among HIV-infected and HIV-exposed infants.
    Laserson KF; Nyakundi D; Feikin DR; Nyambane G; Cook E; Oyieko J; Ojwando J; Rivers SB; Ciarlet M; Neuzil KM; Breiman RF
    Vaccine; 2012 Apr; 30 Suppl 1():A61-70. PubMed ID: 22520138
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Malnutrition levels among vaccinated and unvaccinated children between 2 and 3 years of age following enrollment in a randomized clinical trial with the pentavalent rotavirus vaccine (PRV) in Bangladesh.
    Feller AJ; Zaman K; Lewis KD; Hossain I; Yunus M; Sack DA
    Vaccine; 2012 Apr; 30 Suppl 1():A101-5. PubMed ID: 22520118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.